Quest Diagnostics Revenue 2011-2025 | DGX
Quest Diagnostics annual/quarterly revenue history and growth rate from 2011 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Quest Diagnostics revenue for the quarter ending September 30, 2025 was $2.816B, a 13.18% increase year-over-year.
- Quest Diagnostics revenue for the twelve months ending September 30, 2025 was $10.850B, a 13.74% increase year-over-year.
- Quest Diagnostics annual revenue for 2024 was $9.872B, a 6.7% increase from 2023.
- Quest Diagnostics annual revenue for 2023 was $9.252B, a 6.38% decline from 2022.
- Quest Diagnostics annual revenue for 2022 was $9.883B, a 8.39% decline from 2021.
|
Quest Diagnostics Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $9,872 |
| 2023 | $9,252 |
| 2022 | $9,883 |
| 2021 | $10,788 |
| 2020 | $9,437 |
| 2019 | $7,726 |
| 2018 | $7,531 |
| 2017 | $7,402 |
| 2016 | $7,214 |
| 2015 | $7,493 |
| 2014 | $7,435 |
| 2013 | $7,146 |
| 2012 | $7,383 |
| 2011 | $7,392 |
| 2010 | $7,260 |
|
Quest Diagnostics Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-09-30 | $2,816 |
| 2025-06-30 | $2,761 |
| 2025-03-31 | $2,652 |
| 2024-12-31 | $2,621 |
| 2024-09-30 | $2,488 |
| 2024-06-30 | $2,397 |
| 2024-03-31 | $2,366 |
| 2023-12-31 | $2,288 |
| 2023-09-30 | $2,295 |
| 2023-06-30 | $2,338 |
| 2023-03-31 | $2,331 |
| 2022-12-31 | $2,333 |
| 2022-09-30 | $2,486 |
| 2022-06-30 | $2,453 |
| 2022-03-31 | $2,611 |
| 2021-12-31 | $2,744 |
| 2021-09-30 | $2,774 |
| 2021-06-30 | $2,550 |
| 2021-03-31 | $2,720 |
| 2020-12-31 | $3,002 |
| 2020-09-30 | $2,786 |
| 2020-06-30 | $1,827 |
| 2020-03-31 | $1,822 |
| 2019-12-31 | $1,926 |
| 2019-09-30 | $1,956 |
| 2019-06-30 | $1,953 |
| 2019-03-31 | $1,891 |
| 2018-12-31 | $1,839 |
| 2018-09-30 | $1,889 |
| 2018-06-30 | $1,919 |
| 2018-03-31 | $1,884 |
| 2017-12-31 | $1,865 |
| 2017-09-30 | $1,856 |
| 2017-06-30 | $1,864 |
| 2017-03-31 | $1,817 |
| 2016-12-31 | $1,560 |
| 2016-09-30 | $1,885 |
| 2016-06-30 | $1,906 |
| 2016-03-31 | $1,863 |
| 2015-12-31 | $1,849 |
| 2015-09-30 | $1,880 |
| 2015-06-30 | $1,925 |
| 2015-03-31 | $1,839 |
| 2014-12-31 | $1,883 |
| 2014-09-30 | $1,904 |
| 2014-06-30 | $1,902 |
| 2014-03-31 | $1,746 |
| 2013-12-31 | $1,756 |
| 2013-09-30 | $1,788 |
| 2013-06-30 | $1,815 |
| 2013-03-31 | $1,787 |
| 2012-12-31 | $1,774 |
| 2012-09-30 | $1,822 |
| 2012-06-30 | $1,878 |
| 2012-03-31 | $1,909 |
| 2011-12-31 | $1,761 |
| 2011-09-30 | $1,906 |
| 2011-06-30 | $1,903 |
| 2011-03-31 | $1,822 |
| 2010-12-31 | $1,715 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $19.968B | $9.872B |
| Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Encompass Health (EHC) | United States | $11.598B | 22.30 |
| Elanco Animal Health (ELAN) | United States | $10.678B | 22.39 |
| DaVita (DVA) | United States | $8.733B | 12.75 |
| Chemed (CHE) | United States | $6.156B | 21.62 |
| RadNet (RDNT) | United States | $6.023B | 217.53 |
| Option Care Health (OPCH) | United States | $4.389B | 18.68 |
| LifeStance Health (LFST) | United States | $2.446B | 0.00 |
| Addus HomeCare (ADUS) | United States | $2.090B | 21.58 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.828B | 23.03 |
| Astrana Health (ASTH) | United States | $1.431B | 134.39 |
| U.S Physical Therapy (USPH) | United States | $1.123B | 28.41 |
| Atai Life Sciences (ATAI) | Germany | $1.019B | 0.00 |
| Pennant (PNTG) | United States | $0.884B | 29.36 |
| Daxor (DXR) | United States | $0.063B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.056B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |